Insider Transactions Screener
Search for and identify insider purchases or sales of company shares. The screener offers additional information and analysis on the transactions and allows users to set up alerts and receive notifications when new transactions occur.
| Ticker | Insider | Transaction Type | Ownership Type | Shares Traded | Value / Price | Filing Date |
|---|---|---|---|---|---|---|
|
TDG
|
Robert J Small
Director |
BUY
Grant, award, or other acquisition
|
Direct | 58 Added 0.14% |
$37,470
$646.03 p/Share
|
Mar 28
2022 |
|
TDG
|
David Barr |
BUY
Grant, award, or other acquisition
|
Direct | 58 Added 0.18% |
$37,470
$646.03 p/Share
|
Mar 28
2022 |
|
TDG
|
Jane M. Cronin |
BUY
Grant, award, or other acquisition
|
Direct | 58 Added 13.0% |
$37,470
$646.03 p/Share
|
Mar 28
2022 |
|
TDG
|
Michael Graff |
BUY
Grant, award, or other acquisition
|
Direct | 58 Added 1.21% |
$37,470
$646.03 p/Share
|
Mar 28
2022 |
|
TDG
|
Mervin Dunn
Director |
BUY
Grant, award, or other acquisition
|
Direct | 58 Added 3.73% |
$37,470
$646.03 p/Share
|
Mar 28
2022 |
|
TDG
|
Raymond F Laubenthal
Director |
BUY
Grant, award, or other acquisition
|
Direct | 58 Added 0.04% |
$37,470
$646.03 p/Share
|
Mar 28
2022 |
|
TDG
|
Michele Santana |
BUY
Grant, award, or other acquisition
|
Direct | 58 Added 11.18% |
$37,470
$646.03 p/Share
|
Mar 28
2022 |
|
DLTR
|
Daniel J Heinrich
Director |
BUY
Open market or private purchase
|
Direct | 425 Added 10.63% |
$66,338
$156.09 p/Share
|
Mar 28
2022 |
|
KR
|
Mark C Tuffin
Senior Vice President |
SELL
Sale (or disposition) back to the issuer
|
Direct | 56,039 Reduced 19.66% |
$3,189,179
$56.91 p/Share
|
Mar 28
2022 |
|
KR
|
Mark C Tuffin
Senior Vice President |
BUY
Exercise of conversion of derivative security
|
Direct | 56,039 Added 16.43% |
$1,284,414
$22.92 p/Share
|
Mar 28
2022 |
|
SRE
|
Jeffrey W Martin
Chairman, CEO and President |
SELL
Open market or private sale
|
Direct | 30,796 Reduced 61.52% |
$5,001,270
$162.4 p/Share
|
Mar 28
2022 |
|
BSX
|
Ian T Meredith
EVP Global Chief Med Officer |
SELL
Open market or private sale
|
Direct | 6,588 Reduced 19.0% |
$287,764
$43.68 p/Share
|
Mar 28
2022 |
|
FISV
|
Guy Chiarello
Chief Operating Officer |
SELL
Open market or private sale
|
Direct | 10,000 Reduced 4.41% |
$1,000,400
$100.04 p/Share
|
Mar 28
2022 |
|
FISV
|
Guy Chiarello
Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct | 10,000 Added 4.22% |
$365,400
$36.54 p/Share
|
Mar 28
2022 |
|
RCG
|
Murray Stahl
President/Co-Portfolio Manager |
BUY
Open market or private purchase
|
Indirect | 675 Added 0.2% |
$1,600
$2.37 p/Share
|
Mar 28
2022 |
|
STT
|
Donna De Maio
Director |
BUY
Grant, award, or other acquisition
|
Direct | 181 Added 50.0% |
-
|
Mar 28
2022 |
|
TPL
|
Murray Stahl
Director |
BUY
Open market or private purchase
|
Direct | 3 Added 0.18% |
$4,206
$1401.9 p/Share
|
Mar 28
2022 |
|
TPL
|
Murray Stahl
Director |
BUY
Open market or private purchase
|
Indirect | 17 Added 0.05% |
$23,832
$1401.9 p/Share
|
Mar 28
2022 |
|
BKR
|
General Electric CO
> 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Indirect | 18,146,540 Added 19.28% |
-
|
Mar 28
2022 |
|
BKR
|
General Electric CO
> 10% Shareholder |
SELL
Exercise of conversion of derivative security
|
Indirect | 18,146,540 Reduced 30.89% |
-
|
Mar 28
2022 |
|
FRME
|
Michael R Becher
Director |
BUY
Exercise of conversion of derivative security
|
Direct | 1,500 Added 8.04% |
$18,690
$12.46 p/Share
|
Mar 28
2022 |
|
LLY
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct | 7,538 Reduced 0.01% |
$2,202,227
$292.15 p/Share
|
Mar 28
2022 |
|
NVDA
|
Tench Coxe
Director |
SELL
Open market or private sale
|
Indirect | 100,000 Reduced 2.7% |
$27,406,000
$274.06 p/Share
|
Mar 28
2022 |
|
V
|
Ryan Mcinerney
Chief Executive Officer |
SELL
Open market or private sale
|
Direct | 6,466 Reduced 100.0% |
$1,422,520
$220.0 p/Share
|
Mar 28
2022 |
|
V
|
Ryan Mcinerney
Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct | 6,466 Added 50.0% |
$403,931
$62.47 p/Share
|
Mar 28
2022 |
|
CRM
|
Marc Benioff
Chair and CEO |
SELL
Open market or private sale
|
Direct | 2,300 Reduced 0.01% |
$488,773
$212.51 p/Share
|
Mar 28
2022 |
|
CRM
|
Marc Benioff
Chair and CEO |
BUY
Exercise of conversion of derivative security
|
Direct | 2,300 Added 0.01% |
$186,277
$80.99 p/Share
|
Mar 28
2022 |
|
MSFT
|
Judson Althoff
EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct | 11,012 Reduced 8.05% |
$3,344,124
$303.68 p/Share
|
Mar 28
2022 |
|
RDGL
|
Michael K Korenko
CEO AND PRESIDENT |
BUY
Open market or private purchase
|
Direct | 100,000 Added 1.03% |
$6,000
$0.06 p/Share
|
Mar 28
2022 |
|
IMMR
|
Francis Jose
General Counsel |
SELL
Open market or private sale
|
Direct | 3,915 Reduced 13.09% |
$20,593
$5.26 p/Share
|
Mar 28
2022 |
|
NTRA
|
Michael Burkes Brophy
CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct | 915 Reduced 1.13% |
$36,261
$39.63 p/Share
|
Mar 28
2022 |
|
NTRA
|
Steven Leonard Chapman
CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct | 2,605 Reduced 4.12% |
$103,236
$39.63 p/Share
|
Mar 28
2022 |
|
NTRA
|
Daniel Rabinowitz
SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct | 686 Reduced 0.48% |
$27,186
$39.63 p/Share
|
Mar 28
2022 |
|
NTRA
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct | 134 Reduced 0.02% |
$5,310
$39.63 p/Share
|
Mar 28
2022 |
|
NTRA
|
Robert Alan Schueren
CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct | 1,382 Reduced 50.27% |
$54,769
$39.63 p/Share
|
Mar 28
2022 |
|
LH
|
Peter J Wilkinson
SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct | 915 Reduced 19.84% |
$252,924
$276.42 p/Share
|
Mar 28
2022 |
|
LH
|
Vaart Sandra D Van Der
EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct | 1,792 Reduced 18.81% |
$495,345
$276.42 p/Share
|
Mar 28
2022 |
|
LH
|
Mark S Schroeder
EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct | 1,885 Reduced 17.38% |
$521,052
$276.42 p/Share
|
Mar 28
2022 |
|
LH
|
Paul R Kirchgraber
CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct | 1,648 Reduced 12.15% |
$455,540
$276.42 p/Share
|
Mar 28
2022 |
|
LH
|
Glenn A Eisenberg
Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct | 6,286 Reduced 10.76% |
$1,737,576
$276.42 p/Share
|
Mar 28
2022 |
|
LH
|
Brian J Caveney
EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct | 1,883 Reduced 11.76% |
$520,499
$276.42 p/Share
|
Mar 28
2022 |
|
LH
|
Lance Berberian
EVP, Special Advisor, Strategy |
SELL
Payment of exercise price or tax liability
|
Direct | 2,360 Reduced 10.79% |
$652,351
$276.42 p/Share
|
Mar 28
2022 |
|
SNAX
|
Alex Hawkins
CFO |
BUY
Grant, award, or other acquisition
|
Direct | 25,000 Added 12.35% |
-
|
Mar 28
2022 |
|
FUSN
|
John Valliant
Chief Executive Officer |
SELL
Open market or private sale
|
Direct | 9,600 Reduced 2.55% |
$72,480
$7.55 p/Share
|
Mar 28
2022 |
|
RCAT
|
Jeffrey M Thompson
Chairman of the Board, CEO |
BUY
Open market or private purchase
|
Direct | 1,000 Added 0.01% |
$2,030
$2.03 p/Share
|
Mar 28
2022 |
|
OTIC
|
Paul E Cayer
President and CFBO |
SELL
Open market or private sale
|
Direct | 5,624 Reduced 2.45% |
$13,554
$2.41 p/Share
|
Mar 28
2022 |
|
OTIC
|
Alan Charles Foster
Chief Scientific Officer |
SELL
Open market or private sale
|
Direct | 2,559 Reduced 1.43% |
$6,167
$2.41 p/Share
|
Mar 28
2022 |
|
OTIC
|
Robert Michael Savel Ii
Chief Technical Officer |
SELL
Open market or private sale
|
Direct | 3,325 Reduced 2.23% |
$8,013
$2.41 p/Share
|
Mar 28
2022 |
|
OTIC
|
David Allen Weber
Director |
SELL
Open market or private sale
|
Direct | 11,243 Reduced 2.89% |
$27,096
$2.41 p/Share
|
Mar 28
2022 |
|
PINE
|
Cto Realty Growth, Inc. |
BUY
Open market or private purchase
|
Direct | 100 Added 0.01% |
$1,839
$18.39 p/Share
|
Mar 28
2022 |